Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2023-12-06 10:11:00 ET More on TG Therapeutics TG Therapeutics: Trying To Fill The Gap Back To $20 TG Therapeutics, Inc. (TGTX) Q3 2023 Earnings Call Transcript TG Therapeutics: Q3 Earnings Spike Hard To Explain Given Rival's Numbers TG Therapeutics gains aft...
2023-12-06 09:17:21 ET More on Seattle Genetics Seagen's Acquisition: EU Approval And Potential Upside Seagen gains amid options trades, optimism for FTC approval for Pfizer deal FDA to decide on approving Keytruda/Padcev combo therapy by May 9 Seeking Alpha&...
2023-12-06 04:37:12 ET More on Merck KGaA Merck KGaA (MKGAF) Q3 2023 Earnings Call Transcript Merck KGaA: Company With A Potential Upside Exscientia climbs as Merck KGaA joins AI drug discovery Historical earnings data for Merck KGaA Dividend scorecar...
2023-12-06 01:02:58 ET Summary Ariel Investments' 13F portfolio value decreased by 11% this quarter, from $10.56B to $9.45B. The largest five stakes in the portfolio are Mattel, Baidu, Kennametal, Madison Square Garden Entertainment, and Philip Morris. Stake increases were see...
2023-12-05 22:50:05 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-12-05 10:30:35 ET Summary EyePoint Pharmaceuticals, Inc. EYP-1901, a potential treatment for wet age-related macular degeneration, showed positive results in a Phase 2 study, meeting primary and secondary endpoints. The drug demonstrated non-inferiority to the current standar...
– Phase III (INAVO120) results shows that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line setting – – PIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked t...
2023-12-04 14:53:11 ET More on Roche Holding Roche: Leveraging Nvidia's AI For Genentech's Innovation Be Patient, Roche Is A Clear Buy At This Price Roche Holding AG (RHHBY) Q3 2023 Earnings Call Transcript Roche ventures into weight-loss drug market with $2....
2023-12-04 11:54:15 ET More on Viking Therapeutics Viking Therapeutics, Inc. (VKTX) Q3 2023 - Earnings Call Transcript Viking's Incretin Mimetic Data Fails To Move Stock - Has Mr. Market Moved On? Pfizer hits new 52-week low after weight loss setback Viking T...
2023-12-04 08:26:05 ET More on EyePoint Pharma Shorting EyePoint Pharmaceuticals Ahead Of Davio-2 Wet-AMD Data: Potential 78% Gain Countdown To Clarity: EyePoint's December Data Delivery EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2023 Earnings Conference Call Transcrip...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...